359 related articles for article (PubMed ID: 16272366)
1. Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.
Zhou J; Shen X; Huang J; Hodes RJ; Rosenberg SA; Robbins PF
J Immunol; 2005 Nov; 175(10):7046-52. PubMed ID: 16272366
[TBL] [Abstract][Full Text] [Related]
2. Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression.
Huang J; Khong HT; Dudley ME; El-Gamil M; Li YF; Rosenberg SA; Robbins PF
J Immunother; 2005; 28(3):258-67. PubMed ID: 15838383
[TBL] [Abstract][Full Text] [Related]
3. Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy.
Zhou J; Dudley ME; Rosenberg SA; Robbins PF
J Immunother; 2005; 28(1):53-62. PubMed ID: 15614045
[TBL] [Abstract][Full Text] [Related]
4. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length.
Shen X; Zhou J; Hathcock KS; Robbins P; Powell DJ; Rosenberg SA; Hodes RJ
J Immunother; 2007 Jan; 30(1):123-9. PubMed ID: 17198091
[TBL] [Abstract][Full Text] [Related]
5. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy.
Robbins PF; Dudley ME; Wunderlich J; El-Gamil M; Li YF; Zhou J; Huang J; Powell DJ; Rosenberg SA
J Immunol; 2004 Dec; 173(12):7125-30. PubMed ID: 15585832
[TBL] [Abstract][Full Text] [Related]
6. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro.
Li Y; Liu S; Hernandez J; Vence L; Hwu P; Radvanyi L
J Immunol; 2010 Jan; 184(1):452-65. PubMed ID: 19949105
[TBL] [Abstract][Full Text] [Related]
7. Characterization and comparison of 'standard' and 'young' tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution.
Donia M; Junker N; Ellebaek E; Andersen MH; Straten PT; Svane IM
Scand J Immunol; 2012 Feb; 75(2):157-67. PubMed ID: 21955245
[TBL] [Abstract][Full Text] [Related]
8. Generation of Induced Pluripotent Stem Cells from Human Melanoma Tumor-infiltrating Lymphocytes.
Saito H; Iwabuchi K; Fusaki N; Ito F
J Vis Exp; 2016 Nov; (117):. PubMed ID: 27911363
[TBL] [Abstract][Full Text] [Related]
9. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
10. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8+ T cells for adoptive immunotherapy.
Liu S; Etto T; Rodríguez-Cruz T; Li Y; Wu C; Fulbright OJ; Hwu P; Radvanyi L; Lizée G
J Immunother; 2010 May; 33(4):371-81. PubMed ID: 20386469
[TBL] [Abstract][Full Text] [Related]
11. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
[TBL] [Abstract][Full Text] [Related]
12. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Rosenberg SA; Yang JC; Sherry RM; Kammula US; Hughes MS; Phan GQ; Citrin DE; Restifo NP; Robbins PF; Wunderlich JR; Morton KE; Laurencot CM; Steinberg SM; White DE; Dudley ME
Clin Cancer Res; 2011 Jul; 17(13):4550-7. PubMed ID: 21498393
[TBL] [Abstract][Full Text] [Related]
13. Selective growth, in vitro and in vivo, of individual T cell clones from tumor-infiltrating lymphocytes obtained from patients with melanoma.
Zhou J; Dudley ME; Rosenberg SA; Robbins PF
J Immunol; 2004 Dec; 173(12):7622-9. PubMed ID: 15585890
[TBL] [Abstract][Full Text] [Related]
14. In vivo proliferation of adoptively transferred tumor-infiltrating lymphocytes in mice.
Wong RA; Alexander RB; Puri RK; Rosenberg SA
J Immunother (1991); 1991 Apr; 10(2):120-30. PubMed ID: 2043592
[TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.
Sim GC; Chacon J; Haymaker C; Ritthipichai K; Singh M; Hwu P; Radvanyi L
BioDrugs; 2014 Oct; 28(5):421-37. PubMed ID: 24890028
[TBL] [Abstract][Full Text] [Related]
16. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2.
Heemskerk B; Liu K; Dudley ME; Johnson LA; Kaiser A; Downey S; Zheng Z; Shelton TE; Matsuda K; Robbins PF; Morgan RA; Rosenberg SA
Hum Gene Ther; 2008 May; 19(5):496-510. PubMed ID: 18444786
[TBL] [Abstract][Full Text] [Related]
17. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
18. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
Zippel D; Friedman-Eldar O; Rayman S; Hazzan D; Nissan A; Schtrechman G; Markel G; Schachter J; Itzhaki O; Besser MJ
Anticancer Res; 2019 Sep; 39(9):4995-5001. PubMed ID: 31519606
[TBL] [Abstract][Full Text] [Related]
19. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
Zikich D; Schachter J; Besser MJ
Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
[TBL] [Abstract][Full Text] [Related]
20. Single-Cell Transcriptome Analysis Reveals Gene Signatures Associated with T-cell Persistence Following Adoptive Cell Therapy.
Lu YC; Jia L; Zheng Z; Tran E; Robbins PF; Rosenberg SA
Cancer Immunol Res; 2019 Nov; 7(11):1824-1836. PubMed ID: 31484655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
